PubMed Health⌕ Search

Biomedical subjects

H S Feldman

Publications and source records attributed to H S Feldman.

At least 37 records · Page 2Linked to original sources
PubMed1980

Family therapy: its role in the prevention of criminality.

The family imprints its members with selfhood in all cultures. Absence of family imprints can result in the development of deviant childhood behavior and loss of identity. In two black racial groups in dissimilar world areas and sampling (Kenya, Africa and Newark, N.J.), five familial determinants interfered with the development of culturally accepted family imprints and led to deviant and criminal behavior. It is suggested that if these deterrents, namely poverty, lack of family authority figures, rejection of of the individual child, absence of family cohesiveness, and loss of individual identity within the family, were altered in their development by family therapy techniques, then criminal and deviant behavior would be decreased.

Africa↗
PubMed1979

New antiarrhythmic agents. 1. Primary alpha-amino anilides.

Thirty-two alpha-amino anilides with various substituents in the aromatic ring and in the alpha position are described. Their abilities to protect mice against chloroform-induced fibrillation and to elicit toxicity were determined. Substitution of an alkyl or aryl group in the alpha position enhanced the antifibrillatory activity. In most cases, increased potency was accompanied by increased toxicity. Eleven compounds were tested in dogs with surgically induced myocardial infarction; most showed antiarrhythmic activity. 2-Aminopropiono-2',6'-xylidide, tocainide, was chosen for clinical investigation.

Anilides↗
PubMed1979

New antiarrhythmic agents. 2. Amide alkyl alpha-amino xylidides.

The synthesis of a series of N-alkyl 2-amino 2',6'-xylidides is described. The method involved coupling of the N-alkyl-2',6'-xylidine with the appropriate 2-haloacyl halide, followed by ammonolysis. Alternatively, alkylation of the 2-phthalimido 2',6'-xylidide with NaH and the alkyl halide followed by hydrazinolysis was used. All compounds were evaluated for their ability to protect mice against chloroform-induced ventricular fibrillation. The compounds were generally more potent antifibrillatory agents than the corresponding secondary amides. All were more potent than tocainide and several showed less CNS toxicity. Five compounds were further evaluated in dogs with ventricular arrhythmias resulting from myocardial infarction. N-Ethyl-2-aminoaceto-4'-propoxy-2',6'-xylidide was as potent as lidocaine and produced less CNS toxicity.

Aniline Compounds↗
PubMed1979

New antiarrhythmic agents. 3. Primary beta-amino anilides.

The synthesis and pharmacologic evaluation of primary beta-amino anilides, as well as comparisons with tocainide, lidocaine, and its beta homologue, are described. Substituted anilines were acylated with 3-bromoacyl chlorides and converted to the title compounds by direct amination or via 3-phthalimido anilides and subsequent hydrazinolysis. Alternatively, anilines were acylated with substituted acryloyl chlorides and the amines prepared by addition of ammonia to the double bond. The target compounds were evaluated for their ability to protect against chloroform-induced fibrillation in mice. All were found to have some antifibrillatory activity; several were more potent than tocainide, a compound in clinical trials as an oral antiarrhythmic drug. Four compounds were tested for their effects against ventricular arrhythmias in dogs with myocardial infarction. 3-Amino-2',6'-butyroxylidide (38) was found to be more potent and less CNS toxic than tocainide.

Anilides↗
PubMedDate not supplied

Loxapine succinate as initial treatment of hostile and aggressive schizophrenic criminal offenders.

The efficacy and safety of loxapine were evaluated in 18 acutely ill schizophrenic criminal offenders in the Essex County Jail. The offender patients were treated for three days with intramuscular loxapine (25 mg three or four times a day), followed by seven days of oral concentrate (up to 150 mg/day in three or four divided doses). Psychiatric status was determined with the Brief Psychiatric Rating and the Clinical Global impression scales at the time of admission, after 8, 24, 48, and 72 hours, amd on days 7 and 10 of medication. Three patients did not complete treatment: one was released on bail after 24 hours of therapy, and the other two had adverse reactions (tongue swelling and muscle spasms, each in one patient) which required cessation of treatment. Statistically significant improvement in both rating scale results was evident as early as 8 hours after treatment began. By day 10, all Brief Psychiatric Rating Scale items and factors and the Clinical Global impression results were statistically improved over baseline measurements. At the end of the study, 87 per cent (13/15) of the patients were well enough to cooperate with their attorneys and understand the procedures of the court. Adverse effects (generally extrapyramidal) appeared in four of 18 patients during parenteral administration and in two of 15 patients during oral therapy.

Adult↗